# Terapet

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/terapet

- Industry: Biotechnology
- Headquarters: Geneva, Switzerland
- Website: www.terapet.ch
- Total disclosed funding: $4.7M
- Latest round: Grant (Oct 16, 2026)
- Investors on record: 6

## About

Terapet SA is a Swiss company focused on developing advanced imaging technologies for the healthcare sector, specifically in nuclear medicine and oncology, through innovative products designed to enhance treatment processes.Founded in 2019, Terapet SA, headquartered in Geneva, Switzerland, specializes in advanced imaging technologies for nuclear medicine. The company's founders, Christina Vallgren and Marcus Palm, have directed their efforts towards enhancing quality control in proton therapy. Terapet SA has secured CHF 2.3 mn in funding during its most recent deal on February 17, 2023, from investors including Efficient Frontier Investing, FONGIT, and Nina Capital, marking a significant step in its financial development. The total amount raised by the company is CHF 2.3 mn from a single pre-Series A funding round.Terapet SA specializes in advanced imaging technologies for nuclear medicine, focusing primarily on two flagship products: Qualyscan™ and Nuclyscan™. Qualyscan™ enhances quality control in proton therapy by integrating next-generation imaging capabilities to improve diagnosis and treatment processes in radiotherapy. Nuclyscan™ complements this offering by contributing to advancements in nuclear imaging. These products address critical challenges in precision medicine, serving healthcare institutions, particularly oncology practices and radiotherapy centers globally.Terapet SA generates revenue through direct sales of its imaging solutions, emphasizing B2B transactions within the healthcare industry. The company engages in partnerships with hospitals and radiotherapy clinics, providing advanced technology essential for quality control and imaging in nuclear medicine. Revenue streams consist of one-time purchases of equipment like Qualyscan™ and Nuclyscan™, as well as potential service agreements for ongoing support and maintenance. The company's offerings are designed to meet the growing demand for advanced imaging technologies in cancer care, particularly in precision medicine contexts.In February 2023, Terapet SA raised CHF 2.3 mn in pre-Series A funding to enhance its market reach for its first product and boost research and development efforts. The company plans to expand its presence into new international markets, focusing on regions with high demand for advanced imaging technologies. The recent funding will be pivotal in supporting marketing initiatives and product development, aiming to cement its position in the evolving landscape of nuclear medicine.

## Funding rounds

- Grant, Oct 16, 2026, $3.6M — Innosuisse, KIAT
- Seed, Jul 1, 2020, $1.1M — Fongit Seed Invest, Nina Capital, Efficient Frontier Investing, FONGIT

## Investors

- Fongit Seed Invest (https://capitalatlas.ai/funds/fongit-seed-invest) — Seed
- Nina Capital (https://capitalatlas.ai/funds/nina-capital) — Seed
- Efficient Frontier Investing (https://capitalatlas.ai/funds/efficient-frontier-investing) — Seed
- FONGIT (https://capitalatlas.ai/funds/fongit) — Seed
- Innosuisse — Grant
- KIAT — Grant